Next Article in Journal
A Bacterially-Expressed Recombinant Envelope Protein from Usutu Virus Induces Neutralizing Antibodies in Rabbits
Previous Article in Journal
Chimeric Measles Virus (MV/RSV), Having Ectodomains of Respiratory Syncytial Virus (RSV) F and G Proteins Instead of Measles Envelope Proteins, Induced Protective Antibodies against RSV
Previous Article in Special Issue
Herpes Simplex Virus Type 2 Is More Difficult to Neutralize by Antibodies Than Herpes Simplex Virus Type 1
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 9
Issue 2
10.3390/vaccines9020158
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Vaccine Development for Herpes Simplex Viruses: A Commentary of Special Issue Editors

by
Antonella Caputo
* and
Peggy Marconi
*
Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Fossato di Mortara 64/b, 44121 Ferrara, Italy
*
Authors to whom correspondence should be addressed.
Vaccines 2021, 9(2), 158; https://doi.org/10.3390/vaccines9020158
Submission received: 3 February 2021 / Accepted: 11 February 2021 / Published: 16 February 2021
(This article belongs to the Special Issue Vaccine Development for Herpes Simplex Viruses)
Versions Notes

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Herpes simplex virus type 1 and 2 (HSV1 and HSV2) are global, widespread human pathogens transmitted by direct contact that cause lifelong, recurrent asymptomatic and painful symptomatic clinical illnesses (cold sores, keratitis, blepharitis, meningitis, encephalitis, genital infections), overt disease and severe sequelae in neonatal and immune-compromised patients, and increased risk of cervical cancer and other sexually transmitted infections, including HIV [...]

Share and Cite

MDPI and ACS Style

Caputo, A.; Marconi, P. Vaccine Development for Herpes Simplex Viruses: A Commentary of Special Issue Editors. Vaccines 2021, 9, 158. https://doi.org/10.3390/vaccines9020158

AMA Style

Caputo A, Marconi P. Vaccine Development for Herpes Simplex Viruses: A Commentary of Special Issue Editors. Vaccines. 2021; 9(2):158. https://doi.org/10.3390/vaccines9020158

Chicago/Turabian Style

Caputo, Antonella, and Peggy Marconi. 2021. "Vaccine Development for Herpes Simplex Viruses: A Commentary of Special Issue Editors" Vaccines 9, no. 2: 158. https://doi.org/10.3390/vaccines9020158

APA Style

Caputo, A., & Marconi, P. (2021). Vaccine Development for Herpes Simplex Viruses: A Commentary of Special Issue Editors. Vaccines, 9(2), 158. https://doi.org/10.3390/vaccines9020158

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop